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Wenjie ZengAbstract
Background: Developed countries use generic competition to contain pharmaceutical expenditure. China, as a
developing and transitional country, has not yet deemed an increase in the use of generic products as important;
otherwise, much effort has been made to decrease the drug prices. This paper aims to explore dynamically the
price and use comparison of generic and originator drugs in China, and estimate the potential savings of patients
from switching originator drugs to generics.
Methods: A typical hospital in Chongqing, China, was selected to examine the price and use comparisons of 12
cardiovascular drugs from 2006 to 2011.
Results: The market share of the 12 generic medicines studied in this paper was 34.37% for volume and 31.33% for
value in the second half of 2011. The price ratio of generic to originator drugs was between 0.34 and 0.98, and the
volume price index of originators to generics was 1.63. The potential savings of patients from switching originator
drugs to generics is 65%.
Conclusion: The market share of the generics was lowering and the weighted mean price kept increasing in face
of the strict price control. Under the background of hospitals both prescribing and dispensing medicines, China’s
comprehensive healthcare policy makers should take measures from supply and demand sides to promote the
consumption of generic medicines.
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In recent years, pharmaceutical expenditure worldwide
has rapidly increased and attracted significant attention.
The OECD published a recent report showing that
pharmaceutical expenditure has grown by more than
50% in real terms during the last decade [1]. This in-
crease is driven by a number of factors including stricter
clinical targets, rising patient expectations, aging popula-
tions, and the continued launch of new premium-priced
drugs [2]. Owing to their low price and comparable
quality, generic medicines are used to enhance drug pre-
scription efficiency and thus decrease expenditure [2-4].
In general, generic medicines tend to be 20%–80%
cheaper than originator medicines, especially now with aCorrespondence: wenwin99@sina.com
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reproduction in any medium, provided the orgreater number imported from India (where lower pro-
duction and labor costs apply) into Europe [3].
In addition, multiple supply- and demand-side reforms
have been instigated in various European countries for
existing drugs. Supply-side reforms include pricing re-
forms such as volume agreements with payback mecha-
nisms for over budget situations and compulsory price
cuts, as well as measures to obtain low prices for ge-
nerics [5-11]. Demand-side measures, collated under the
four Es—education, engineering, economics, and en-
forcement [5]—include general practitioners’ incentives
to prescribe generic drugs [12-14], pharmacists’ use of
generics in substitution for originator drugs [15-18], and
consumers’ attitudes to generic drugs [17-20]. These
measures have resulted in some progress; e.g., there has
been an increase in the use of generics in Portugal [21],
generic substitution has been welcomed in Finland [17],is is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nerics in France [22]. However, there is a continuing
need for countries to look to the experiences of other
nations to determine which measures are most appropri-
ate for them [21].
China is also challenged by the increased financial pres-
sure in medicine use, especially with the development of
its health care reform. Since the initiation of economic re-
forms in 1979, the social and economic structures associ-
ated with the health sector reform have undergone
significant changes. This has resulted in a decreased reli-
ance on state funding, an increase in the cost of medical
care, reduced public financing, and increased funding by
user fees. In addition, individual health insurance cover in
China decreased from approximately 70% in 1981 to only
20% percent in 1993. However, this rate increased with the
2003 implementation of a new insurance scheme, namely
the New Rural Cooperative Medical Insurance Scheme. In
2009, the total medical insurance coverage rate was 93%
[23]. As a proportion of total health expenditure, out-of-
pocket payments rose from 20% in 1978 to 60% in 2001,
and then fell to 36% in 2010. Outpatient and inpatient
expenditure on pharmaceuticals from 1990 to 2010 are
displayed in Table 1. In 2010, the pharmaceutical revenue
of Chinese public hospitals amounted to 405.39 billion
CNY (approximately US$62.37 billion), representing
45.80% of total business revenue [24].
It must also be noted that the supply chain of generic
medicines in China has its own characteristics. Owing to
the changing economic system, the Chinese government
reformed its pharmaceutical distribution network from a
centrally controlled supply system to a market-oriented
system. Thus, a competitive mechanism has been intro-
duced into the pharmaceutical market, and acts to im-
prove the availability of pharmaceuticals. Under this
supply chain, domestic pharmaceutical production grew
dramatically while numerous imported drugs began to
enter into the Chinese market.
Products
Companies that wish to supply generic medicines are now
asked to provide information regarding bioequiavailabilityTable 1 Average per capita pharmaceutical expenditures for
Year Average medical charges
for per outpatient
Medicine fee Proportion
1990 10.9 7.4 67.9
1995 39.9 25.6 64.2
2000 85.8 50.3 58.6
2005 126.9 66 52.1
2008 146.5 74 50.5
2009 159.5 81.2 50.9
2010 173.8 88.1 50.7before they can obtain authorization to enter the market.
From 1986 to 2006, Chinese firms have independently
developed only 40 categories of chemical medicines
[25]. However, before 2007, the State Food and Drug
Administration (SFDA) had approved 177,000 drug appli-
cations [25], meaning that most of the drug applications
belonged to generics. In practice, the SFDA has adopted
looser restrictions for drug registration, which gave so-
called new drug licenses to minor reformulations or where
only the dosage or packing of existing products were
changed. In October 2007, to enhance the focus on drug
safety while encouraging innovation, “Measures on the
Administration of Drug Registration” were employed to
improve the existing registration procedures by upgrading
drug appraisal and approval standards.
Manufacturers
China currently has more than 5,000 drug manufactur-
ing firms. Most of these are small-scale pharmaceutical
businesses with a scattered geographical layout and du-
plicated production processes. These firms produce
mainly generic drugs with little development of origin-
ator pharmaceuticals. However, China’s fast growing
economy and large population have meant that the
pharmaceutical market has expanded tremendously, with
an annual average growth of 16.1% in recent years [26].
The total output value rose from 137.1 billion RMB in
1998 to 667.9 billion RMB in 2007 [26]. After experien-
cing several quality issues, the government concentrated
on the strict implementation of the Good Manufacturing
Practice to assure product quality.
Price
Drug prices are determined by three administration au-
thorities according to elementary indications and cost
information. For state-priced products, the National De-
velopment and Reform Commission (NDRC) sets max-
imum retail prices (price cap); for province- or
municipality-priced products, the price management de-
partment determines the retail prices; and for other
products the ex-factory and retail prices are determined
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medicines (e.g., antibiotics, cardiovascular drugs, and an-
ticancer drugs) the NDRC implemented 28 price adjust-
ments between 1997 and 2011 [27]. Before entering
catalogs for hospital procurement, the above medicines
are subject to tenders for provision in each province and
municipality, and procurement prices for hospitals are
then determined. For cardiovascular drugs, the price was
changed four times between 2006 to 2011 in Chongqing
Urban District: two changes were invitations for tenders
in March 2006 and April 2011, and two were attributed
an NDRC adjustment of maximum retail prices in January
2007 and March 2011.
Market
By the end of 2007 China had 13,000 wholesale pharma-
ceutical enterprises, 341,000 retail pharmaceutical enter-
prises and chain store enterprises, and 554,000 rural
drug supply outlets [26]. These sales agents use sales
commissions, tourism, kickbacks, and gifts to hospital
managers and/or doctors who purchase or prescribe
their products. The commercial promotional activities
and profits of multi-layered distribution is a substantial
component of the total costs of pharmaceuticals.
Data from the Datamonitor Group offer an insight
into China’s generic market. The Chinese generics mar-
ket grew by 11.3% in 2010 to reach a value of US
$19,645.3 million. The compound annual growth rate of
the market in the period 2006–2010 was 16.4%. The
Chinese generics market shrank by 0.2% in 2010 to
reach a volume of 95.3% of total pharmaceutical volume.
The compound annual rate of change of the market in
the period 2006–2010 was −0.2%.
Physicians
In China, hospital physicians prescribe and dispense drugs,
which means that every hospital has had its own pharmacy,
dispensing more than 80% of China’s total medicine con-
sumption; the remaining 20% of medicine is distributed by
community drug stores [26]. The current reimbursement
system used in pharmaceutical expenditure in Chinese hos-
pitals induces dispensing doctors (DDs) to overprescribe
drugs to patients and to prescribe drugs that produce the
greatest profit for themselves [28]. Furthermore, the profit
markups that DDs might receive from drug prescriptions
are determined by the price of the medicines. In a compara-
tive study, Lim expressed that DDs prescribed more medi-
cines to patients than their non-dispensing counterparts
[29]. Research from other regions in Southeast Asia also
reinforced the notion that physicians could profit by both
prescribing and dispensing drugs, and that more originator
drugs were prescribed than generic drugs [30].
The “Prescription Management Ordinance” promul-
gated by the Chinese government in 2007 specified thatprescriptions should be written using generic names or
INN (international nonproprietary names). However, this
ordinance has done little to increase the use of generics.
For example, prescription sheets indicate brand name or
manufacturer name, or these are already selected in the
hospital’s electronic information system. Although pre-
scription sheets can be filled in community pharmacies,
and generic substitution for originator prescriptions is
common in developed countries, such practices are rare
in Chinese hospitals and community pharmacies.
Owing to the high number of pharmaceutical factories
in China and low-priced products, it is hoped that the
use of generics will eventually increase. However, the
generic market in China has its own characteristics. In
this paper, a dynamic perspective is taken with principal
cardiovascular drugs to reveal the current situation
concerning generic use, market share, and price compar-
isons. This will provide us with the fundamental infor-
mation required to explore potential measures to
promote the use of generic drugs in China.
Methods
Data source
As stated above, under the current situation of no SPD,
80% of drugs are sold in hospitals, and drug prices for
hospital procurement are determined by a tender
process in each province and municipality. Price varia-
tions for hospital drugs exist in each district, even in the
same city, and these prices are constantly changing.
Therefore, we chose data from one restricted district,
i.e., Chongqing, to compare price and use evolutions.
Chongqing is a municipality directly under China’s
central government. It is located in Southwest China
with a total population of 23 million people. The leading
therapeutic drug classes consumed in its hospitals were
identified as anti-infective agents, and medicines for car-
diovascular, digestive, and nervous systems [31]. Because
of frequent price fluctuations, product variations, policy
changes, and specific prescribing patterns, anti-infective
agents were not suitable for this research. In contrast,
cardiovascular drugs involve many pharmaceuticals for
chronic diseases, and their long-term usage with rela-
tively stable products made them suitable for this study,
and in the study period the drug price was the most im-
portant factors affecting the utilization structure. Other
researchers have also studied this kind of medicine
[7,32]. We chose a typical hospital in which to conduct
our investigation, i.e., a hospital affiliated to the Third
Military Medical University, which is one of the largest
hospitals in Southwest China. It is also a typical health
provider because of the services it provides to the
public.
The dataset was obtained from the magazine company
of China Pharmacy (an authoritative Chinese Journal).
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makes it easy for it to collect detailed information from
the larger hospitals in Southwest China. The dataset
contains all individual delivery information including
product name, purchase date, dosage form, specification,
manufacturer, unit price, and purchase volume, which
was collated from the hospital’s procurement records.
Selection of generic and originator medicines
In this research, originator medicines are referred to as
products once possessing intellectual property, and al-
most all these medicines are global products provided by
international pharmaceutical enterprises including Bayer,
Pfizer, and AstraZeneca et al. Generic drugs are domes-
tic chemical products produced by enterprises with local
investments, and most of the medicines are in strong
competition with a number of manufacturers.
A set of different drug classes (each class containing
one originator and one or more generic drugs of the
same chemical entity) were chosen to compare their
market share and price evolution. Based on our dataset
and other reports, the three most prescribed drug
groups in cardiovascular medicines were chosen for this
study, including calcium channel blockers with mainly
vascular effects, sartans, and statins [7,32]. Of the 19
matched products, 12 products were used in this study.
Some products with relatively high usage rates were not
used (such as Fluvastatin, Pitavastatin, and Losartan) be-
cause they lacked data from domestic generic products.
Price calculation, comparison
Ordinarily, three kinds of drug prices are used in price
comparison research, i.e., ex-manufacturer price, whole-
sale price, and retail price. The retail price policy of the
hospital pharmacy has been adjusted several times, and
the markup has decreased from 50% to approximately
15% (in some districts it has been reduced to zero in
2012). In this paper, the hospital’s procurement price
was adopted to avoid eventual retail price discrepancies.
The Chinese currency renminbi (RMB) “yuan” is used to
determine the price and value, and the exchange rate
was RMB 6.12 to US$1.00 on September 12, 2013.
We employed defined daily doses (DDDs) as a standard
unit of measurement according to the World Health
Organization definitions of these 12 products [33,34], and
used the price per DDD (DDDc) to empirically measure
the procurement price set. That is, we transformed the
directly observable procurement price (Pp) into DDDc
using a equation: DDDc = (Pp/Q) ×DDD, where Q indi-
cates the dosage unit per package (or strength of product).
The prices of the individual and overall 12 products
were assayed by adopting a weighted mean price, which
were calculated by dividing market value by market vol-
ume. For the price comparison of generic and originatordrugs in 2011, the price index (Pvolume) was calculated










where Volumei indicates the total volume (DDDs) of a
medicine, and poriginator or pgenerics indicates the weighted
mean price (DDDc, Pw).
We took six months as the analysis period, because
one year is too long to express the volume change and
one quarter is too short to remove possible anomalies.
And we used “1H” to represent the first half year and
“2H” for the second half year.
Results
Market share of generic and originator drugs
The market share for volume of generic drugs decreased
from approximately 50% in the first half year of 2006 to
34.37% in the second half year of 2011, and that of ori-
ginator drugs increased to 65.63% (Figure 1). A continu-
ous decrease in generics market share could be observed
in the early years until it reached its stable platform in
the first half year of 2008 and maintained narrow fluctu-
ations in the following years.
The evolution of the market share for value was more
complicated. The value share of generic drugs also
steadily decreased in the early years until it reached its
valley floor (23.52%) in the first half of 2008, and then it
increased slowly to 31.33%.
Price and use evolution
The overall weighted mean price (DDDc) and total volume
(DDDs) of 12 cardiovascular medicines from 2006 to 2011
were calculated and presented in Figure 2. The half-year
total volume of generic and originator drugs increased con-
tinuously, but the increase rate of originator drugs was
much higher than that of the generics. The weighted mean
price of generics was also in a rising channel, in contrast
with the originator drugs, which attributed to the sharp
price decline of Simvastatin by its manufacturer Merck Co.
to compete for market share in the end of 2009.
Price comparison and potential savings
Because some of the products were not purchased, espe-
cially generic drugs in the early study years, we
employed the latest data (2011) to compare the price of
generic and originator medicines.
We used the proportion of the individual volume in
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Time / half year
Market share Generic drugs Originator drugs
a.Volume (DDDs) b.Value 
Figure 1 Market shares of originator and generic cardiovascular drugs from 2006 to 2011. The market shares were displayed with 100%
stacked column chart. Each panel indicates the percentage of originator and generic drugs, and the cumulative proportion of each stacked
element always totals 100%.
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generic and originator drugs are displayed as DDDc in
Table 2. The ratios of DDDc of generic to originator
medicines ranged from 0.34 to 0.98. The volume index
of originator to generics was 1.63. Thus, the price of ori-
ginator drugs is 63% higher than generics.
For all 12 brand-name drugs, generic drugs were available
in the identical form with lower prices. We could estimate
the potential savings from more consistent use of generic
drugs for each individual medication in the following way:
Potential savingsoriginator





























Figure 2 Overall weighted mean price (DDDc) and volume (DDDs) ofThe potential savings from general substitution of
these 12 originator drugs in 2011 is 4.19 million RMB,
with a proportion of 66% for originator utilization.
Principal generic products
Among the generic drugs with the highest DDDc (with
the exception of Pravastatin Sodium launched late in
2009), two products, i.e., Amlodipine and Atorvastatin
Calcium, showed significant increase of use in the study
period, especially in recent years (see Figure 3). The
market shares of these two products were 43.01% and
30.80% for general value in 2011, which were much
higher than for other products. This reveals an ex-

























12 cardiovascular medicines from 2006 to 2011.











Nifedipine 1.57 4 4.47 Bayer 0.35
Amlodipine 4.68 4 4.78 Pfizer 0.98
Felodipine 1.61 1 3.27 AstraZeneca 0.49
Lacidipine 1.27 1 3.68 GlaxosmithKline 0.34
Simvastatin 2.94 1 3.97 Merck 0.74
Pravastatin Sodium 5.80 1 7.04 Sankyo 0.82
Atorvastatin Calcium 7.73 2 9.22 Pfizer 0.84
Irbesartan 3.21 1 4.47 Sanofi-Synthelabo 0.72
Irbesartan and Hydrochlorothiazide 3.19 1 4.47 Sanofi-Synthelabo 0.71
Losartan Potassium and Hydrochlorothiazide 3.90 1 5.89 Merck 0.66
Valsartan 2.41 1 5.76 Novartis 0.42
Telmisartan 1.74 1 2.44 Boehringer Ingelheim 0.71
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ginator drugs was much lower, ranging from 4.10% to
17.82% in value, with the only exception of Lacidipine at
just 0.73%.
Discussion
The results in this paper reveal the current situation re-
garding 12 generic cardiovascular medicines in a hospital
in China:
- -Total volume: There was an obvious increase in the
use of both generic and originator medicines. In the
second half of 2011, the volume of prescribed generics
was 4.27 times that in the beginning of the study

























Figure 3 Price (DDDc) and volume (DDDs) evolution of generic amlodip- -Market share: In the second half of 2011, the market
share of the 12 generic medicines decreased to 34.37%
for volume (DDDs) and 31.33% for value, compared
with 48.64% (volume) and 36.65% (value) at the
beginning of the study period.
- -Price comparison: The price ratios of generic to
originator drugs were between 0.34 and 0.98, and the
volume price index of originator to generics was 1.63.
Thus, the price of originator drugs is 63% higher than
generics for volume. The weighted mean price of
generics shows an increasing trend.
- -Special products: Two principal generic products,
i.e., amlodipine and atorvastatin calcium, occupied
43.01% and 30.80% of the market share in generic





















ine and atorvastatin calcium.
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As a general trend, pharmaceutical consumption in
China has experienced a significant increase in recent years.
The increase in cardiovascular drug consumption can be
attributed to a number of reasons, including urbanization,
an aging of population accompanied by an increase of
chronic diseases, the expansion of the scope of medical in-
surance, and improvements in living standards. Using the
experience of other countries for reference, generic substi-
tution can decrease pharmaceutical expenditure, with a po-
tential saving of 66% for patients by switching from
originator to generic drugs. This result is similar to the re-
sults from a study on four generic medicines in China
(which showed a 65% saving) [35], and a further study that
found a 60% reduction in costs where patients used generic
substitutions in 17 middle-income countries [36].
However, the increasing trend of the weighted mean
price of generics, the lowering market share of generics,
and the fact that just two principal generic products
enjoy a substantially higher market share, can be largely
explained by changes in the consumption structure,
suggesting that more higher priced drugs were pre-
scribed than cheaper ones by hospital physicians (this
can be observed in Figures 1 and 2 by contrasting the
evolution of the volume and value market share of gen-
eric and originator drugs). For example, the abnormal
phenomenon in generic drug use of two principal gen-
eric products might be attributed to the relatively higher
DDDs, which would bring greater economic interests to
the whole supply chain from the prescribing and dis-
pensing of these two drugs.
We can learn two lessons from these results. The first
concerns the current state of the Chinese health sector,
where hospitals prescribe and dispense drugs. From an-
other point of view, this paper also reveals the attitudes of
DDs to generic medicines, because most drugs are con-
sumed according to doctors’ prescriptions. Owing to the
financial incentives of DDs as incompetent agents and
nontransparent price and quality information for patients,
DDs may prescribe more expensive drugs than needed.
The second implication regards the drug price policy
employed in China in recent years. Although the direct
price cut or invitation for tenders can affect drug costs
in the short term, the pharmaceutical supply chain ad-
justs the product structure and increases the weighted
mean price in the long term. In contrast, the average
price of medicines has dropped in recent years by
43.18% in European countries with high generic market
shares and by 21.56% in low market share countries [3].
Generic competition, in general, changes the market
and decreases the price of medicines. The creation of a
sustainable generic pharmaceutical market requires activeregulatory and marketing measures at all levels including
incentives for manufactures, physicians, and dispensers
[7,37]. For China’s comprehensive healthcare policy
makers, there is a long way to go before an appropriate
system to promote the consumption of generic medicines
can be established, especially under the background of
hospitals both prescribing and dispensing medicines. Po-
tential measures should stem from supply and demand
sides, including a corresponding policy for greater trans-
parency in the pricing of generics, restrictive prescription
regulations for physicians, health education to ensure the
greater acceptance of generics by patients, and a reim-
bursement system for the prescription of generics [38,39].
This research is subject to some limitations, for example,
the data collection was from just one region, one hospital,
and one indication; this occurred because data from com-
munity drugstores are not easy to collect. The market share
of generics may not represent all hospitals, but the price ra-
tio of originator to generics did reveal the situation in
Chongqing hospitals, and thus does show the current situ-
ation in Chinese hospitals. In addition, the effect of trad-
itional Chinese medicine was not included in this study,
which might have a substantial effect on the usage struc-
ture of chemical products. Furthermore, some new drugs
were also launched during the study period from 2006 to
2011; these were few and any effect was not apparent.
Conclusions
This study is the first dynamic exploration of the price
and use comparison of generic and originator drugs in a
Chinese hospital. The market share of the generics was
lowering and the weighted mean price kept increasing in
face of the strict price control. And two principal generic
products with relatively high DDDc occupied most of the
market shares in generic value, suggesting an extremely
abnormal phenomenon in general utilization. Under the
background of hospitals both prescribing and dispensing
medicines, China’s comprehensive healthcare policy makers
should take measures from supply and demand sides to
promote the consumption of generic medicines.
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